Addisons Disease Therapeutics Market by Therapy, End-user, and Geography - Forecast and Analysis 2023-2027

The Global Addison's disease therapeutics market size is estimated to grow by USD 442 million between 2022 and 2027 and the size of the market is forecast to increase at a CAGR of 6.93%. Factors such as the reformulation of drugs, production of special drug designations, and advanced diagnostics procedure are helping patients fight Addison's disease which in turn is driving the market growth. Additionally, diagnostic tests as clinical guidelines are also influencing the market growth. Vendors are also focussing on the production of oral drugs and parenteral drugs to treat the disease. With new innovations, competitors are expected to face high challenges in the market. For instance, Leading vendors such as Pfizer Inc. and Merck and Co. Inc., are expected to face huge competition from the emerging vendor, Diurnal. Diurnal received regulatory approvals for its products Alkindi and Chronocort and has already launched these products in the major market, including the US, Europe, and Japan. Such launches associated with the entry of new players is expected to lead the market toward further fragmentation during the forecast period.

This report extensively covers market segmentation by end-user (hospitals, clinics, and diagnostic laboratories), therapy (oral drugs and parenteral drugs), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

 What will the Size of the Addison's Disease Therapeutics Market be During the Forecast Period?

To learn more about this report, Download the FREE Report Sample

Addison's Disease Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

The special drug designation( is notably driving Addison's disease therapeutics market growth, although factors such as delay in diagnosis may impede the market growth. Our researchers studied the data for years, with 2022 as the base year and 2023 as the estimated year, and presented the key drivers, trends, and challenges for the market. Although there has been a decrease in demand for the market during the COVID-19 pandemic, a holistic analysis of drivers will help companies refine marketing strategies to gain a competitive advantage.   

Key Addison's Disease Therapeutics Market Driver

The special drug designation is the key factor driving the global Addison's disease therapeutics market growth. Under the Orphan Drug Act (ODA) of 1983, the drugs indicated for treating rare diseases are referred to as 'orphan drugs.' In the US, a rare disease is defined as a condition that affects less than 200,000 people. Similarly, in the EU, a disease is defined as rare if it affects less than five in 10,000 people.

Rare diseases are not as prevalent as mainstream conditions, such as diabetes, asthma, and hypertension. Hence, manufacturers often hesitate to invest large amounts in the research and development (R&D) of drugs for the treatment of rare diseases such as neuroblastoma. Federal regulatory bodies such as the US FDA support manufacturers through public programs, acts, policies, and other incentives to encourage the development of drugs to treat rare diseases. This, in turn, drives market growth.

Key Addison's Disease Therapeutics Market Trend

The expanding research into the development of regenerative therapy will fuel the global Addison's disease therapeutics market growth. The current treatment options involve the life-long use of exogenous corticosteroids. The long-term use of these drugs predisposes the patients to a series of harmful side effects, including muscle weakness, buffalo hump, headache, facial hair growth, puffiness of the face (moon face), glaucoma, hypernatremia, and cataract. To reduce the duration of treatment and overcome these side effects, researchers are focusing on developing regenerative therapies for treating Addison's disease.

The adoption of regenerative medicine is expected to increase owing to its minimal side effects and curative nature. Various research institutions, as well as companies, are focusing on investing in the R&D of these medicines for curing rare and orphan diseases, including Addison's disease, along with chronic illnesses such as central nervous system disorders, cardiovascular disorders, and cancers.

Key Addison's Disease Therapeutics Market Challenge

Delayed diagnosis is a major challenge to the global Addison's disease therapeutics market growth. The clinical manifestations and the symptoms of Addison's disease are often subtle and non-specific, because of which the disease often goes underdiagnosed. Some of the common symptoms of Addison's disease include hyperpigmentation, fatigue, anorexia, orthostasis, nausea, muscle and joint pain, and craving for salt. These symptoms progress gradually and are often ignored until stress or illness unmasks the deficiency of cortisol and mineralocorticoids. Since the disease is a rare clinical manifestation, it is often misdiagnosed as another condition, resulting in a life-threatening adrenal crisis.

The diagnostic delay can be by the patient or at the primary, or secondary care level, leading to increased chances of morbidity and mortality. The lack of awareness regarding the signs and symptoms of Addison's disease, especially in developing countries, is responsible for the diagnostic delays at the patient level. The failure to diagnose the disease at the early stage results in its progression to the chronic stage, which limits the use of hormonal replacement therapy and increases the mortality associated with the disease.

Key Addison's Disease Therapeutics Market Customer Landscape

Our analysis of the Life Cycle of the market indicates a movement from the innovator’s stage to the laggard’s stage. The report illustrates the lifecycle of the market, focusing on the adoption rates of the major countries including the US, Canada, Germany, the UK, and Japan. Technavio has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop growth strategies from 2022 to 2027.

Global Addison's Disease Therapeutics Market Customer Landscape

Who are the Major Addison's Disease Therapeutics Market Vendors?                                     

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market

actizapharma.com - The company offers Addison's disease therapeutics such as AXSYM Cortisol. Also, the company is involved in manufacturing, exporting, and distributing generic, branded, and other allied pharmaceutical products.

We also have detailed analyses of the market’s competitive landscape and offer information on 15 market vendors, including :

• Akorn Operating Co. LLC
• Amneal Pharmaceuticals Inc.
• Bristol Myers Squibb Co.
• Neurocrine Biosciences Inc.
• Hikma Pharmaceuticals Plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• GlaxoSmithKline Plc
• Abbott Laboratories
• Amgen Inc.
• Eli Lilly and Co.
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Bio-Techne Corp.
• Lupin Ltd.
• BTL Biotechno Labs Pvt. Ltd.
• Bayer AG

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Addison's Disease Therapeutics Market?

The market share growth by the oral drugs segment will be significant during the forecast period. Oral drugs are the first-line treatment for Addison's disease and are indicated to restore the levels of corticosteroids in patients. As they are administered through the mouth, they have good patient compliance, owing to which the segment dominates the global Addison's disease therapeutics market.

Get a glance at the market contribution of various segments Request a PDF Sample

The oral drugs segment showed a gradual increase in market share with USD 698.77 million in 2017 and will continue to grow by 2021. Although the market remains dominated by generic drugs, the growth of this segment is expected to accelerate due to the availability of reformulated versions of existing corticosteroid preparations. The modified-release dosage forms of oral drugs offer significant pharmacokinetic and pharmacodynamic advantages, leading to more effective treatment, which enhances the patient adherence ratio. Owing to these advantages, the newer versions of oral drugs have gained traction among end-users, which is expected to lead to their increased uptake by patients and, in turn, is expected to propel the growth of the market segment during the forecast period. Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.

The growth of this segment is primarily attributed to the increasing adoption of Addison's Disease Therapeutics, which is driven by an increase in the global demand for the Addison's Disease Therapeutics Industry.

Which are the Key Regions for Addison's Disease Therapeutics Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to contribute 41% of market growth by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The presence of favourable reimbursement schemes in the region exerts a positive impact on disease control among patients. Government and private healthcare insurers in the US are striving to improve patient access to medicines by providing full-time coverage for drugs, including corticosteroids. For instance, the Medicare Advantage Prescription Drug and the Medicare Part D programs provide full-time coverage for hydrocortisone preparations (oral and parenteral). The availability of reimbursement policies attracts many patients to take these drugs for disease management, which is expected to drive the growth of the Addison's disease therapeutics market in North America during the forecast period.

This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. The outbreak of COVID-19 led to a decline in the demand for Addison's disease therapeutics in North America. Countries across North America were severely affected by the COVID-19 pandemic in 2020. The COVID-19 pandemic greatly influenced the healthcare business, causing major disruptions throughout the supply chain, right from raw material procurement and manufacturing to delivery in 2020.  These factors led to the shutdown of the manufacturing units of several industries. This, in turn, resulted in the slow growth of the Addison's disease therapeutics market in North America. However, in 2021 business and industrial activities resumed with the relaxation of lockdown restrictions due to the availability of COVID-19 vaccines and the vaccination drives carried out by the governments of different countries such as the US, Canada, and Mexico, which, in turn, is expected to grow during the forecast period.

Segment Overview

Our report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by therapy, end-user, and region.

• Therapy Outlook (USD Million, 2017 - 2027)
  • Oral drugs
  • Parenteral drugs

• End-user Outlook (USD Million, 2017 - 2027)
  • Hospitals
  • Clinics
  • Diagnostic laboratories

• Region Outlook (USD Million, 2017 - 2027)
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Argentina
    • Australia
    • Brazil
    • Rest of the World

Parent Market Analysis

Technavio categorizes the global Addison's disease therapeutics market as a part of the pharmaceutical market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Addison's Disease Therapeutics Market Scope
Report Coverage	Details
Page number	157
Base year	2022
Historical year	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 6.93%
Market growth 2023-2027	USD 442 million
Market structure	Fragmented
YoY growth (%)	5.85
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 41%
Key consumer countries	US, Canada, Germany, UK, and Japan
Competitive landscape	Leading companies, Competitive Strategies, Consumer engagement scope
Key companies profiled	Actiza Pharmaceutical Pvt. Ltd., Akorn Operating Co. LLC, Amneal Pharmaceuticals Inc., Bristol Myers Squibb Co., Neurocrine Biosciences Inc., Hikma Pharmaceuticals Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Amgen Inc., Eli Lilly and Co., Biogen Inc., Boehringer Ingelheim International GmbH, Bio-Techne Corp., Lupin Ltd., BTL Biotechno Labs Pvt. Ltd., and Bayer AG
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Addison's Disease Therapeutics Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the Addison's disease therapeutics market between 2023 and 2027
• Precise estimation of the size of the Addison's disease therapeutics market and its contribution to the parent market.
• Accurate predictions about  upcoming trends and changes in consumer behaviour
• Growth of the Addison's disease therapeutics industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive details of factors that will challenge the growth of Addison's disease therapeutics market vendors

 

We can help! Our analysts can customize this report to meet your requirements. Get in touch